GlaxoSmithKline (LON:GSK)‘s stock had its “underperform” rating restated by stock analysts at Credit Suisse in a report issued on Thursday, American Banking & Market News reports. They currently have a GBX 1,500 ($24.72) price target on the stock. Credit Suisse’s price target points to a potential downside of 7.35% from the stock’s previous close. Shares […]
GlaxoSmithKline Receives “Underperform” Rating from Credit Suisse (GSK) is a post from: Zolmax
The post GlaxoSmithKline Receives “Underperform” Rating from Credit Suisse (GSK) appeared first on Zolmax.